美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ARIA Opportunities ETF

26.10

+0.98633.93%

盤後：25.11-0.9863-3.78%16:10 EDT

成交量：23

成交額：620

市值：1,260.92萬

市盈率：- -

高：26.10

開：25.11

低：26.10

收：25.11

52周最高：26.36

52周最低：24.54

股本：48.32萬

流通股本：48.32萬

量比：0.07

換手率：0.00%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

ARIA Opportunities ETF

交易所：

ARCA

成立時間：

- -

員工人數：

- -

公司地址：

10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States

官網：

http://www.ariad.com

郵編：

73120

電話：

傳真：

405-896-5825

簡介：

ARIAD Pharmaceuticals, Inc.的前景是通過具有突破性的藥物治療癌症患者。該公司致力於發現、開發和推廣小分子藥物來治療癌症患者，滿足患者最迫切的醫療需求——目前無法治療的侵略性癌症。該公司的目標是建立一個完全集成的腫瘤學公司。該公司目前有三個正在開發中的候選產品。白血病藥物Ponatinib正處於血液腫瘤患者臨床試驗的第一階段和第二階段，包括慢性髓性白血病和費城陽性急性淋巴細胞白血病的臨床試驗。藥物AP26113正處於治療晚期實體腫瘤的臨床試驗的第一階段和第二階段。藥物Ridaforolimus正處於研究不同類型癌症患者的多個臨床試驗中。根據附註2所述的許可協議的條款，默克股份有限公司（ Merck, Sharpe & Dohme Corp. ）負責藥物Ridaforolimus相關的開發、製造和推廣活動。除了公司的主導發展計劃，該公司重點放在分子靶向癌症細胞信號通路的小分子療法的針對性藥物研發項目。該公司於1991年4月在特拉華州註冊成立。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/ARIA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIA Opportunities ETF","latestPrice":26.0951,"timestamp":1789156800000,"preClose":25.1088,"halted":0,"volume":23,"hourTrading":{"tag":"盘后","latestPrice":25.1088,"preClose":26.0951,"latestTime":"16:10 EDT","volume":4,"amount":104.3804,"timestamp":1789157404248,"change":-0.9863,"changeRate":-0.037796,"amplitude":0},"delay":0,"changeRate":0.03928104887529472,"floatShares":483200,"shares":483200,"eps":0,"marketStatus":"休市中","change":0.9863,"latestTime":"09-11 16:00:00 EDT","open":25.1088,"high":26.0951,"low":26.0951,"amount":620,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":25.1088,"nav":26.11,"aum":12618145,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.1088,"preClose":26.0951,"latestTime":"16:10 EDT","volume":4,"amount":104.3804,"timestamp":1789157404248,"change":-0.9863,"changeRate":-0.037796,"amplitude":0},"volumeRatio":0.07320178463404789},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":483200,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.07320178463404789,"shares":483200,"dividePrice":0,"high":26.0951,"amplitude":0,"preClose":25.1088,"low":26.0951,"week52Low":24.5362,"pbRate":"--","week52High":26.36,"institutionHeld":0.5771,"latestPrice":26.0951,"eps":0,"divideRate":0,"volume":23,"delay":0,"ttmEps":0,"open":25.1088,"prevYearClose":24.76,"prevWeekClose":25.9602,"prevMonthClose":25.4145,"prevQuarterClose":24.76,"fiveDayClose":26.1719,"twentyDayClose":26.0317},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1992791129,"address":"10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States","zipCode":"73120","officePhone":"405-778-8377","officeFax":"405-896-5825"},"stockCompanyDetail":{"websiteUrl":"http://www.ariad.com","stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0539},{"period":"ytd","weight":0.0539}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"ARIAD Pharmaceuticals, Inc.的前景是通過具有突破性的藥物治療癌症患者。該公司致力於發現、開發和推廣小分子藥物來治療癌症患者，滿足患者最迫切的醫療需求——目前無法治療的侵略性癌症。該公司的目標是建立一個完全集成的腫瘤學公司。該公司目前有三個正在開發中的候選產品。白血病藥物Ponatinib正處於血液腫瘤患者臨床試驗的第一階段和第二階段，包括慢性髓性白血病和費城陽性急性淋巴細胞白血病的臨床試驗。藥物AP26113正處於治療晚期實體腫瘤的臨床試驗的第一階段和第二階段。藥物Ridaforolimus正處於研究不同類型癌症患者的多個臨床試驗中。根據附註2所述的許可協議的條款，默克股份有限公司（ Merck, Sharpe & Dohme Corp. ）負責藥物Ridaforolimus相關的開發、製造和推廣活動。除了公司的主導發展計劃，該公司重點放在分子靶向癌症細胞信號通路的小分子療法的針對性藥物研發項目。該公司於1991年4月在特拉華州註冊成立。","exchange":"ARCA","name":"ARIA Opportunities ETF","nameEN":"ARIA Opportunities ETF"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":null}}